| |
Periodic table of the elements science and academic information, elements and advanced materials data, scientific presentations and all pages, designs, concepts, logos, and color schemes herein are the copyrighted proprietary rights and intellectual property of American Elements. American Elements is a U.S. Registered Trademark. © 2001-2009. American Elements. All rights reserved. |
 |
|
Recent Research & Development for Yttrium
- Liver transplantation after radioembolization in a patient with unresectable HCC.
Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, Wiseman GA, Misra VL.
Nat Rev Gastroenterol Hepatol. 2009 Nov;6(11):679-83.
PMID: 19881519 [PubMed - in process]
- Assessment of Neodymium:Yttrium-Aluminum-Garnet (Nd:YAG) laser fiber wear and tear grade during visual laser ablation of prostatic adenoma.
Rózanski W, Klimek L, Jablonowski Z, Sosnowski M.
Photomed Laser Surg. 2009 Oct;27(5):799-805.
PMID: 19878030 [PubMed - in process]
- Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option.
Saxena A, Bester L, Chua TC, Chu FC, Morris DL.
Ann Surg Oncol. 2009 Oct 30. [Epub ahead of print]
PMID: 19876691 [PubMed - as supplied by publisher]
- Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma.
Fleming CJ, Andrews JC, Wiseman GA, Gansen DN, Roberts LR.
J Vasc Interv Radiol. 2009 Nov;20(11):1460-3.
PMID: 19875064 [PubMed - in process]
- Genotoxic effects of 1064-nm Nd:YAG and 532-nm KTP lasers on fibroblast cell cultures.
Senturk N, Bedir A, Bilgici B, Aydin F, Okuyucu A, Ozmen ZC, Turanli AY.
Clin Exp Dermatol. 2009 Oct 23. [Epub ahead of print]
PMID: 19874333 [PubMed - as supplied by publisher]
- Axillary hair removal with 1064-nm Nd:YAG laser increases sweat production.
Aydin F, Pancar GS, Senturk N, Bek Y, Yuksel EP, Canturk T, Turanli AY.
Clin Exp Dermatol. 2009 Oct 23. [Epub ahead of print]
PMID: 19874331 [PubMed - as supplied by publisher]
- The management of treatment-resistant biliary calculi using percutaneous endourologic techniques.
Ray AA, Davies ET, Duvdevani M, Razvi H, Denstedt JD.
Can J Surg. 2009 Oct;52(5):407-12.
PMID: 19865576 [PubMed - in process]
- [Liver chemoembolization: an update.]
Roche A.
Bull Cancer. 2009 Oct 29. [Epub ahead of print] French.
PMID: 19864205 [PubMed - as supplied by publisher]
- Results of intraocular lens implantation with capsular tension ring in subluxated crystalline or cataractous lenses in children.
Das P, Ram J, Brar GS, Dogra MR.
Indian J Ophthalmol. 2009 Nov-Dec;57(6):431-6.
PMID: 19861744 [PubMed - in process]
- Quantitative PCR Analysis for Bcl-2/IgH in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma.
Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, Hagenbeek A, Morschhauser F, Putz B, Lister A, Rohatiner A.
J Clin Oncol. 2009 Oct 26. [Epub ahead of print]
PMID: 19858392 [PubMed - as supplied by publisher]
- Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study.
Lewandowski RJ, Riaz A, Ryu RK, Mulcahy MF, Sato KT, Kulik LM, Gates VL, Baker T, Omary R, Salem R.
J Vasc Interv Radiol. 2009 Oct 23. [Epub ahead of print]
PMID: 19854068 [PubMed - as supplied by publisher]
- The Role of Tumor Vascularity in Predicting Survival after Yttrium-90 Radioembolization for Liver Metastases.
Sato KT, Omary RA, Takehana C, Ibrahim S, Lewandowski RJ, Ryu RK, Salem R.
J Vasc Interv Radiol. 2009 Oct 19. [Epub ahead of print]
PMID: 19846320 [PubMed - as supplied by publisher]
- Safety and Efficacy Assessment of Flow Redistribution by Occlusion of Intrahepatic Vessels Prior to Radioembolization in the Treatment of Liver Tumors.
Bilbao JI, Garrastachu P, Herráiz MJ, Rodríguez M, Ińarrairaegui M, Rodríguez J, Hernández C, de la Cuesta AM, Arbizu J, Sangro B.
Cardiovasc Intervent Radiol. 2009 Oct 20. [Epub ahead of print]
PMID: 19841973 [PubMed - as supplied by publisher]
- Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A.
Oncologist. 2009;14 Suppl 2:41-51.
PMID: 19819923 [PubMed - in process]
- Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A.
Oncologist. 2009;14 Suppl 2:17-29.
PMID: 19819921 [PubMed - in process]
- Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M.
Oncologist. 2009;14 Suppl 2:4-16.
PMID: 19819920 [PubMed - in process]
- Imaging in targeted delivery of therapy to cancer.
Dancey G, Begent RH, Meyer T.
Target Oncol. 2009 Oct 8. [Epub ahead of print]
PMID: 19838639 [PubMed - as supplied by publisher]
- Polymerization of Enantiopure Monomers Using Syndiospecific Catalysts: A New Approach To Sequence Control in Polymer Synthesis.
Kramer JW, Treitler DS, Dunn EW, Castro PM, Roisnel T, Thomas CM, Coates GW.
J Am Chem Soc. 2009 Oct 16. [Epub ahead of print]
PMID: 19835375 [PubMed - as supplied by publisher]
- [Minimally invasive tumor ablation in the liver]
Wybranski C, Mohnike K, Ricke J.
Anasthesiol Intensivmed Notfallmed Schmerzther. 2009 Oct;44(10):670-7; quiz 679. Epub 2009 Oct 15. German.
PMID: 19834832 [PubMed - in process]
- Intraarticular adalimumab in a patient with pigmented villonodular synovitis.
Kobak S.
Rheumatol Int. 2009 Oct 10. [Epub ahead of print]
PMID: 19820943 [PubMed - as supplied by publisher]
|
Recent Research & Development for Yttrium Metal
- Structures and Spectroscopic Properties of Bis(phthalocyaninato) Yttrium and Lanthanum Complexes: Theoretical Study Based on Density Functional Theory Calculations.
J Phys Chem A Mol Spectrosc Kinet Environ Gen Theory. 2007 Jan 18;111(2):392-400.
- Office-based and microlaryngeal applications of a fiber-based thulium laser.
Ann Otol Rhinol Laryngol. 2006 Dec;115(12):891-6.
- Treatment of cystic craniopharyngiomas with yttrium-90 colloid solution.
Neurosurg Focus. 1997 Dec 15;3(6):e6.
- Percutaneous lumbar discectomy with a working endoscope and laser assistance.
Neurosurg Focus. 1998 Feb 15;4(2):e9.
- Urinary yttrium excretion and effects of yttrium chloride on renal function in rats.
Biol Trace Elem Res. 2006 Winter;114(1-3):225-36.
- A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates.
In Vivo. 2006 Nov-Dec;20(6A):711-4.
- Treatment of gingival hyperpigmentation by erbium-doped:yttrium, aluminum, and garnet laser for esthetic purposes.
J Periodontol. 2007 Jan;78(1):177-84.
- Evidence of the efficacy of radiation synovectomy with yttrium-90: Comment on the article by Jahangier et al.
Arthritis Rheum. 2006 Dec 28;56(1):386 [Epub ahead of print] No abstract available.
- An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives.
Contrast Media Mol Imaging. 2006 Sep;1(5):196-211.
- Synthesis of yttria-based crystalline and lamellar nanostructures and their formation mechanism.
Small. 2005 Jan;1(1):112-21.
|
Material Safety Data Sheet |
1 Identification of substance
- Product details
- Trade name Yttrium ingot
|
2 Composition/Data on components:
- Chemical characterization:
Designation: (CAS#)
Yttrium (CAS# 7440-65-5), 100%
- Identification number(s):
- EINECS Number: 231-174-8
|
3 Hazards identification
- Hazard designation: · void
- Information pertaining to particular dangers for man and environment
Not applicable
|
4 First aid measures
- After inhalation
Supply fresh air. If required, provide artificial respiration. Keep patient warm. Consult doctor if symptoms persist.
Seek immediate medical advice.
- After skin contact
Instantly wash with water and soap and rinse thoroughly.
Seek immediate medical advice.
- After eye contact
Rinse opened eye for several minutes under running water. Then consult doctor.
- After swallowing Seek medical treatment.
|
5 Fire fighting measures
- Suitable extinguishing agents Extinguishing powder. Do not use water.
- For safety reasons unsuitable extinguishing agents
Water.
Halocarbon extinguisher
- Protective equipment:
Wear self-contained breathing apparatus.
Wear full protective suit.
|
6 Accidental release measures
- Person-related safety precautions:
Wear protective equipment. Keep unprotected persons away.
Ensure adequate ventilation
- Measures for environmental protection:
Do not allow material to be released to the environment without proper governmental permits.
- Measures for cleaning/collecting: Collect mechanically.
- Additional information:
See Section 7 for information on safe handling
See section 8 for information on personal protection equipment.
See Section 13 for information on disposal.
|
7 Handling and storage
- Handling
- Information for safe handling:
Keep containers tightly sealed.
Store in cool, dry place in tightly closed containers.
No special precautions necessary if used correctly.
- Information about protection against explosions and fires:
Fine powder: highly flammable
- Storage
- Requirements to be met by storerooms and containers:
No special requirements.
- Information about storage in one common storage facility:
Store away from air.
Do not store together with acids.
Store away from oxidizing agents.
Store away from halogens.
Do not store together with alkalis (caustic solutions).
- Further information about storage conditions:
Avoid contact with air / oxygen.
Keep container tightly sealed.
Store in cool, dry conditions in well sealed containers.
|
8 Exposure controls and personal protection
- Additional information about design of technical systems:
Properly operating chemical fume hood designed for hazardous chemicals and having an average face velocity of at least 100 feet per minute.
- Components with critical values that require monitoring at the
workplace:
Yttrium and compounds, as Y
mg/m3
ACGIH TLV 1
Austria MAK 1
Belgium TWA 1
Denmark TWA 1
Finland TWA 1
France VME 1
Germany TWA 5
Korea TLV 1
Netherlands MAC-TGG 1
Norway TWA 1
Poland TWA 1
Switzerland MAK-W 1
United Kingdom TWA 1; 3-STEL
OSHA PEL 1
- Additional information: No data
- Personal protective equipment
- General protective and hygienic measures
The usual precautionary measures should be adhered to in handling the chemicals.
Keep away from foodstuffs, beverages and food.
Instantly remove any soiled and impregnated garments.
Wash hands during breaks and at the end of the work.
- Breathing equipment: Use breathing protection with high concentrations.
- Protection of hands: Impervious gloves
- Eye protection: Safety glasses
- Body protection: Protective work clothing.
|
9 Physical and chemical properties:
- General Information
- Form: Solid.
- Colour: Grey
- Smell: Odourless
- Value/Range Unit Method
- Change in condition
- Melting point/Melting range: 1522 ° C
- Boiling point/Boiling range: 2927 ° C
- Sublimation temperature / start: Not determined
- Flash point: Not applicable
- Inflammability (solid, gaseous) Product is not inflammable.
- Ignition temperature: Not determined
- Decomposition temperature: Not determined
- Danger of explosion: Product is not explosive.
- Critical values for explosion:
- Lower: Not determined
- Upper: Not determined
- Steam pressure: Not determined
- Density at 20 ° C 4.472 g/cm³
- Solubility in / Miscibility with
- Water: Insoluble
|
10 Stability and reactivity
- Thermal decomposition / conditions to be avoided:
No decomposition if used and stored according to specifications.
- Materials to be avoided:
Acids
Halogens
Bases
Water/moisture
Air
Light
- Dangerous reactions: Contact with acids releases flammable gases
- Dangerous products of decomposition: Metal oxide
|
11 Toxicological information
- Acute toxicity:
- Primary irritant effect:
- on the skin: Powder: irritant effect
- on the eye: Powder: irritant effect
- Sensitization: No sensitizing effect known.
- Additional toxicological information:
To the best of our knowledge the acute and chronic toxicity of this substance is not fully known.
No classification data on carcinogenic properties of this material is available from the EPA, IARC, NTP, OSHA or ACGIH.
|
12 Ecological information:
- General notes:
Do not allow material to be released to the environment without proper governmental permits.
Generally not hazardous for water.
|
13 Disposal considerations
- Product:
- Recommendation
Consult state, local or national regulations for proper disposal.
Hand over to disposers of hazardous waste.
Must be specially treated under adherence to official regulations.
- Uncleaned packagings:
- Recommendation:
Disposal must be made according to official regulations.
|
14 Transport information
- Land transport ADR/RID and GGVS/GGVE (cross-border/domestic)
- ADR/RID-GGVS/E Class: None
- Maritime transport IMDG/GGVSea:
- IMDG/GGVSea Class: None
- Air transport ICAO-TI and IATA-DGR:
- ICAO/IATA Class: None
- Transport/Additional information:
Not dangerous according to the above specifications.
|
15 Regulatory information
- Designation according to EC guidelines:
Observe the normal safety regulations when handling chemicals
The product is not subject to identification regulations under EC Directives and the Ordinance on Hazardous Materials (GefStoffV).
- National regulations
- Information about limitation of use:
For use only by technically qualified individuals.
- Water hazard class: Generally not hazardous for water.
|
16 Other information:
Employers should use this information only as a supplement to other information gathered by them, and should make independent judgement of suitability of this information to ensure proper use and protect the health and safety of employees. This information is furnished without warranty, and any use of the product not in conformance with this Material Safety Data Sheet, or in combination with any other product or process, is the responsibility of the user.
|
|
|
oval in numerous standard diameters from 0.02 to 6.0 inches and wall thicknesses from 0.003 to 0.500 inches.Tubing can be further processed to produce rings, washers, sleeves and sheaths. Custom configurations are also available. 
Materials include most metals including the rare earth metals and other advanced materials. Tubes can also be produced from custom materials and alloys for commercial and research applications and for new proprietary technologies. Other available shapes include bar or plate form, as well as custom machined shapes and through other processes such as nanoparticles (See also application discussion at Nanotechnology Information and at Quantum Dots) and in the form of solutions and organometallics. See research below. We also produce Yttrium as rod, pellets, powder, pieces, granules, ingot, wire, and in compound forms, such as oxide. Other shapes are available by request.
